Cell- and Tissue-Based Therapy
"Cell- and Tissue-Based Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
Descriptor ID |
D064987
|
MeSH Number(s) |
E02.095.147
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cell- and Tissue-Based Therapy".
Below are MeSH descriptors whose meaning is more specific than "Cell- and Tissue-Based Therapy".
This graph shows the total number of publications written about "Cell- and Tissue-Based Therapy" by people in this website by year, and whether "Cell- and Tissue-Based Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 | 2011 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2013 | 1 | 0 | 1 | 2014 | 1 | 0 | 1 | 2015 | 3 | 0 | 3 | 2016 | 3 | 1 | 4 | 2019 | 0 | 1 | 1 | 2020 | 0 | 2 | 2 | 2021 | 0 | 1 | 1 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell- and Tissue-Based Therapy" by people in Profiles.
-
Roy I, Smilnak G, Burkart M, Hamilton E, Thorp K, Miyata S, Ma S, Pro B, Winter J, Gordon L, Karmali R. Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Br J Haematol. 2022 04; 197(1):71-75.
-
Albin RL, Kordower JH. Reply to: "Cell Therapy for Huntington's Disease: Learning from Failure". Mov Disord. 2021 03; 36(3):788-789.
-
Kordower JH, Okun MS, Jankovic J. Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
-
Albin RL, Kordower JH. A Failed Future. Mov Disord. 2020 08; 35(8):1299-1301.
-
Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, Wang TP, Lekakis LJ. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020 04; 61(4):940-943.
-
Poulin MF, Deka A, Mohamedali B, Schaer GL. Clinical Benefits of Stem Cells for Chronic Symptomatic Systolic Heart Failure: A Systematic Review of the Existing Data and Ongoing Trials. Cell Transplant. 2016 11; 25(11):1911-1923.
-
Henry TD, Schaer GL, Traverse JH, Povsic TJ, Davidson C, Lee JS, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Patel AN, Riedel N, Junge C, Hunt A, Kereiakes DJ, White C, Harrington RA, Schatz RA, Losordo DW. Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. Cell Transplant. 2016; 25(9):1701-1711.
-
Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016 Jun 11; 387(10036):2412-21.
-
Henry TD, Schaer GL, DeMaria A, Recker D, Remmers AE, Goodrich J, Patel AN. The ixCELL-DCM Trial: Rationale and Design. Cell Transplant. 2016; 25(9):1689-1699.
-
Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis. 2015 Aug; 21(8):1809-16.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|